MY138680A - N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors - Google Patents

N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Info

Publication number
MY138680A
MY138680A MYPI20042517A MYPI20042517A MY138680A MY 138680 A MY138680 A MY 138680A MY PI20042517 A MYPI20042517 A MY PI20042517A MY PI20042517 A MYPI20042517 A MY PI20042517A MY 138680 A MY138680 A MY 138680A
Authority
MY
Malaysia
Prior art keywords
ring
alkyl
aryl
sulfonylmethylalkyl
heteroaryl
Prior art date
Application number
MYPI20042517A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
David Waterson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY138680(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY138680A publication Critical patent/MY138680A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
MYPI20042517A 2003-06-27 2004-06-25 N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors MY138680A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds

Publications (1)

Publication Number Publication Date
MY138680A true MY138680A (en) 2009-07-31

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20042517A MY138680A (en) 2003-06-27 2004-06-25 N-{4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyformamide compounds as metalloproteinase inhibitors

Country Status (33)

Country Link
US (1) US7485644B2 (OSRAM)
EP (1) EP1644340B1 (OSRAM)
JP (1) JP4701167B2 (OSRAM)
KR (1) KR20060026440A (OSRAM)
CN (2) CN102229589A (OSRAM)
AR (1) AR044931A1 (OSRAM)
AT (1) ATE414063T1 (OSRAM)
AU (1) AU2004251104B2 (OSRAM)
BR (1) BRPI0411929A (OSRAM)
CA (1) CA2529468A1 (OSRAM)
CO (1) CO5650254A2 (OSRAM)
CY (1) CY1108757T1 (OSRAM)
DE (1) DE602004017733D1 (OSRAM)
DK (1) DK1644340T3 (OSRAM)
ES (1) ES2315675T3 (OSRAM)
HR (1) HRP20090009T3 (OSRAM)
IL (1) IL172615A0 (OSRAM)
IS (1) IS8257A (OSRAM)
MX (1) MXPA05013460A (OSRAM)
MY (1) MY138680A (OSRAM)
NO (1) NO20060444L (OSRAM)
NZ (1) NZ544208A (OSRAM)
PL (1) PL1644340T3 (OSRAM)
PT (1) PT1644340E (OSRAM)
RU (1) RU2351595C2 (OSRAM)
SA (1) SA04250224B1 (OSRAM)
SE (1) SE0301922D0 (OSRAM)
SI (1) SI1644340T1 (OSRAM)
TW (1) TW200524898A (OSRAM)
UA (1) UA81491C2 (OSRAM)
UY (1) UY28387A1 (OSRAM)
WO (1) WO2005000822A1 (OSRAM)
ZA (1) ZA200510458B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
RS52229B (sr) * 2005-10-26 2012-10-31 Merck Serono Sa. Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
KR101822444B1 (ko) * 2010-07-08 2018-01-26 가켄 세이야쿠 가부시키가이샤 N-히드록시포름아미드 유도체 및 그를 함유하는 의약

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
KR20020005769A (ko) * 1999-06-04 2002-01-17 다비드 에 질레스 메탈로프로테이나제의 억제제
MXPA02008111A (es) * 2000-02-21 2002-11-29 Astrazeneca Ab N-hidroxiformamidas substituidas con piperidina y piperazina como inhibidores de metaloproteinasas.
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
BR0309671A (pt) * 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
JP2006527754A (ja) * 2003-06-19 2006-12-07 セルテック アール アンド ディ リミテッド Cd23分断阻害物質としてのヒドロキサム酸スルホンアミド

Also Published As

Publication number Publication date
US20070197542A1 (en) 2007-08-23
PT1644340E (pt) 2009-01-02
RU2351595C2 (ru) 2009-04-10
IL172615A0 (en) 2006-04-10
DE602004017733D1 (de) 2008-12-24
CN102229589A (zh) 2011-11-02
SE0301922D0 (sv) 2003-06-27
TW200524898A (en) 2005-08-01
ATE414063T1 (de) 2008-11-15
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
HK1086835A1 (en) 2006-09-29
CA2529468A1 (en) 2005-01-06
SI1644340T1 (sl) 2009-02-28
CY1108757T1 (el) 2014-04-09
AU2004251104B2 (en) 2008-05-08
MXPA05013460A (es) 2006-03-09
PL1644340T3 (pl) 2009-04-30
JP4701167B2 (ja) 2011-06-15
CO5650254A2 (es) 2006-06-30
BRPI0411929A (pt) 2006-08-15
WO2005000822A1 (en) 2005-01-06
CN1812974A (zh) 2006-08-02
CN1812974B (zh) 2011-06-29
ES2315675T3 (es) 2009-04-01
JP2007516164A (ja) 2007-06-21
AR044931A1 (es) 2005-10-12
IS8257A (is) 2006-01-23
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
DK1644340T3 (da) 2009-02-02
UY28387A1 (es) 2005-01-31
EP1644340B1 (en) 2008-11-12
RU2005141058A (ru) 2006-07-27
HRP20090009T3 (en) 2009-02-28
AU2004251104A1 (en) 2005-01-06
UA81491C2 (en) 2008-01-10
EP1644340A1 (en) 2006-04-12
KR20060026440A (ko) 2006-03-23
US7485644B2 (en) 2009-02-03

Similar Documents

Publication Publication Date Title
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
SE0400284D0 (sv) Novel compounds
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
DK1625126T3 (da) Imidazo- og thiazolopyridiner som JAK3-kinaseinhibitorer
DK1052254T3 (da) Nitrogen-holdig heterocykliske derivater og medicin deraf
RU2007110629A (ru) Ингибиторы днк-пк
DK0385237T3 (da) 2-(1-Piperazinyl)-4-phenylcycloalkanopyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende dem
TW200635585A (en) Monocyclic substituted methanones
EA200801828A2 (ru) Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
UA86013C2 (ru) Производные арилалкилкарбаматов, их получение и применение в лечении
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
NO20001402L (no) Substituerte kromanderivater
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
CY1108757T1 (el) Ενωσεις ν-{'4-υποκατεστημενη πιπεραζινη-1-σουλφονυλμεθυλαλκυλ}-ν-υδροξυφορμαμιδιου ως αναστολεις της μεταλλοπρωτεϊνασης.
EA200101204A1 (ru) Новые бициклические соединения аминопиразинона, способ их получения и содержащие их фармацевтические композиции
NO20055657L (no) Nye bioisostaererav aktinonin
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
JP2007515383A5 (OSRAM)
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
NO20026004D0 (no) Nye podofyllotoksinkarbamat- og tiokarbamatforbindelser, fremgangsmåte vedderes fremstilling og farmasöytiske sammensetninger inneholdendedem